Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890539 | 0.79 | MAOA (0.49) | MAOAALDH1A1ROCK1TP53ALOX12 | |
| SCHEMBL17324731 | 0.75 | HTT (0.51) | MAOAALDH1A1ROCK1TP53ALOX12 | |
| SCHEMBL2885349 | 0.73 | TP53 (0.46) | ALDH1A1TP53ALOX12HTTSMN1; SMN2 | |
| SCHEMBL2891386 | 0.73 | HTT (0.56) | ALDH1A1TP53ALOX12HTTRAB9A | |
| SCHEMBL29092087 | 0.72 | SMN1; SMN2 (0.44) | ALDH1A1TP53HTTRAB9ASMN1; SMN2 | |
| SCHEMBL17321500 | 0.72 | ROCK1 (0.48) | MAOAALDH1A1ROCK1TP53ALOX12 | |
| SCHEMBL15241806 | 0.69 | ALDH1A1 (0.49) | MAOAALDH1A1TP53ALOX12HTT | |
| SCHEMBL4414691 | 0.69 | HSD11B1 (0.57) | ALDH1A1HTTSMN1; SMN2POLBMAPT | |
| SCHEMBL12203848 | 0.68 | ALDH1A1 (0.51) | ALDH1A1RAB9APOLBMAPTGAA | |
| SCHEMBL23399438 | 0.67 | NR4A3 (0.53) | ALDH1A1USP2RAB9APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | MAOA 1109/4885ALDH1A1 712/4885ROCK1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.